Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06969586

The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy

Sponsor: University Hospital Dubrava

View on ClinicalTrials.gov

Summary

The goal of this study is to learn if topical ROCK inhibitors protect endothelial corneal cells in patients with glaucoma and Fuchs endothelial corneal dystrophy after cataract surgery. The main question it aims to answer is: do topical ROCK inhibitors decrease the loss of corneal endothelial cells after cataract surgery? Researchers will compare topical ROCK inhibitor to a placebo (a look-alike substance that contains no drug) Participants will: Take topical ROCK inhibitor or a placebo every day for 4 weeks after cataract surgery and visit the clinic for checkups and tests.

Official title: The Effect of Topical Rho-kinase (ROCK) Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy (FECD)

Key Details

Gender

All

Age Range

40 Years - 90 Years

Study Type

OBSERVATIONAL

Enrollment

50

Start Date

2025-04-01

Completion Date

2026-10-01

Last Updated

2025-05-14

Healthy Volunteers

No

Interventions

DRUG

Netarsudil 0.02% Ophthalmic Solution

Topical Netarsudil 0.02% 1x daily for 30 days postoperatively

DRUG

artificial tear substitute

Topical artificial tear substitute 1x daily for 30 days postoperatively.

Locations (1)

University Hospital Dubrava

Zagreb, Croatia